REFERENCES
- Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother 2001; 48 (1): 37–45.
- Martin SJ, Jung R, Garvin CG. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and uri-nary tract infections. Drug Saf 2001; 24 (3): 199–222.
- Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17 (4): 331–341.
- Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27 (5): 887–892.
- Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M. Pharmacokinetics and pharmacodynamics of lev-ofloxacin 500 mg bid IV in ICU patients with early-onset ven-tilator- associated pneumonia. Clin Pharmacokinet 2003; 42 (6): 589–598.
- PF, Pavan F, Nascimben E, et al. Levofloxacin dispo-sition in cerebrospinal fluid of patients with external ventricu-lostomy. Antimicrob Agents Chemother 2003; 47 (10): 3104–3109.
- Rowland M,Tozer TN, Clinial Pharmacokinetics. Concepts and applications. 3rd ed Williams & Wilkins. 1995
- Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Jama 1998; 279 (2): 125–129.
- Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37 (5): 1073–1081.
- Glantz SA, Primer of biostatistics. 5th ed McGraw Hill. 2002
- Naber CK, Hammer M, Kinzig-Schippers M, Sorgel F, Naber KG. Urinary excretion and bactericidal activities of lev-ofloxacin versus ciprofloxacin in healthy volunteers after a sin-gle oral dose of 500 mg. Abstract at the 9th Int Congress of Infectious Diseases, Buenos Aires Argentina 2000; Poster 10920.
- Costerton JW. Introduction to biofilm. Int J Antimicrob Agents 1999; 11 (3-4): 217–221.
- Goto T, Nakame Y, Nishida M, Ohi Y. Bacterial biofilms and catheters in experimental urinary tract infection. Int J Antimicrob Agents 1999; 11 (3-4): 227–231.
- NCCLS. Performance standards for antimicrobial sus-ceptibility testing: twelth informational supplement. 2002; 22: M100–S12
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31–41.